A Single Oral Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Subjects Including a Single Intravenous Microdose of RO6836191
Latest Information Update: 07 Nov 2021
At a glance
- Drugs RO 6836191 (Primary) ; RO 6836191 (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 03 Nov 2016 Status changed from recruiting to completed.
- 04 Dec 2013 New trial record